Merck Expects Expedited Filing Of HDL-Cholesterol Drugs Using Existing Data
Executive Summary
Merck believes it will be able to submit its developmental atherosclerosis therapies targeting HDL cholesterol without conducting major outcomes trials, Merck Research Lab President Peter Kim said during the firm's annual business review in Whitehouse Station, N.J. Dec. 15
You may also be interested in...
Merck To Improve R&D Output By Having More Clues At The Start
Merck's strategy for increasing its research and development productivity relies upon gaining more information about compounds and targets earlier in development, Merck Research Labs President Peter Kim said Dec. 12
Merck To Improve R&D Output By Having More Clues At The Start
Merck's strategy for increasing its research and development productivity relies upon gaining more information about compounds and targets earlier in development, Merck Research Labs President Peter Kim said Dec. 12
Merck To Await Additional Torcetrapib Data Before Advancing CETP Agent
Merck will await further data regarding Pfizer's terminated HDL/LDL compound torcetrapib/Lipitor before moving forward with its own cholesteryl ester transfer protein inhibitor